Qurocom "Acquires Additional 4.7 Billion KRW Shares of Subsidiary Smagen for New Drug and Vaccine Development"

[Asia Economy Reporter Kim Heung-soon] Qurocom announced on the 8th that it will additionally acquire 1,011,588 shares of its new drug and vaccine research and development affiliate, Smagen, for approximately 4.7 billion KRW. After the acquisition, Qurocom's stake in Smagen will be 64.8%. The scheduled date for the stock acquisition is the 9th. The company stated that the purpose of the stock acquisition is "the development of COVID-19 vaccines and AIDS vaccines, and the improvement of financial structure."

This content was produced with the assistance of AI translation services.